share_log

Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

Benzinga Real-time News ·  Jul 15, 2022 10:28

Morgan Stanley analyst Jeffrey Hung maintains Evofem Biosciences (NASDAQ:EVFM) with a Underweight and lowers the price target from $2 to $0.75.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment